Endpoint  ,Name  ,Description  ,Timeframe  
,European Quality of Life 5-Dimension (EQ-5D)  ,Mean percent change from baseline in EQ-5D score  ,"Weeks 16, 52  "
,Work Productivity and Activity Impairment Questionnaire: Psoriasis  (WPAI: PSO)  ,Mean change in WPAI domain scores  ,"Weeks 16, 52  "
,Treatment-emergent Adverse events  ,"Frequency and incidence rate of any TEAE by SOC, PT, severity, and relationship of adverse events (AEs) to investigational product  (IP).  ",During double-blinded treatment and throughout the duration of the apremilast treatment  
,"Clinically significant changes in body weight, waist circumference, vital signs, and/or laboratory findings  ","Frequency of clinically significant changes in body weight, waist circumference, vital signs, and/or laboratory findings.  ",During double-blinded treatment and throughout the duration of the apremilast treatment  
Exploratory  ,,,

,Static Physician Global Assessment (sPGA) of Visible locations  ,"Proportion of subjects who achieve sPGA score of 0 or 1 (among subjects randomized with moderate to severe psoriasis in visible areas, defined as sPGA ≥ 3, which include the dorsal hand, face, neck, or hairline)  ","Weeks 16, 32, 52  "
,Scalp Physician Global Assessment (ScPGA)  ,"Proportion of subjects who achieve ScPGA score of 0 or 1 (among subjects randomized with moderate to severe scalp psoriasis, ScPGA ≥ 3)  ","Weeks 16, 32, 52  "
,Nail Psoriasis Severity Index  (NAPSI)  ,"Proportion of subjects who achieve NAPSI score of 0 in the target fingernail (among subjects randomized with presence of nail psoriasis, defined as onycholysis and onychodystrophy in at least 2 fingernails)  ","Weeks 16, 32, 52  "
